Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner F L, Penault-Llorca F, Perez E A, Thompson E A, Symmans W F, Richardson A L, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm D L, Allison K H, Reis-Filho J S, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S
Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium.
Institute of Pathology, Charité -University Hospital, Berlin, Germany.
Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.
The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC.
A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches.
The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.
随着肿瘤浸润淋巴细胞（TILs）这一免疫生物标志物的临床相关性证据不断增强，乳腺癌（BC）中TILs的形态学评估正日益受到关注。越来越多的证据表明，通过评估苏木精和伊红（H&E）染色的肿瘤切片，肿瘤组织中淋巴细胞浸润程度可作为一个主要参数进行评估。TILs已被证明具有预后价值和潜在的预测价值，尤其是在三阴性乳腺癌和人表皮生长因子受体2过表达的乳腺癌中。
现在需要一种标准化的TILs评估方法，作为将该参数纳入标准组织病理学实践、研究环境以及临床试验的先决条件。本文回顾了目前关于BC中TILs临床有效性和实用性的数据，以期在这个快速发展的领域增进了解和认识，并开发一种在H&E切片上进行视觉评估的标准化方法，同时认可分子/多重方法的未来潜力。
所提供的方法足够详细，可为未来研究提供统一应用的、实用的起点，并提高TILs测量的一致性和可重复性。
